MOESM1 of Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes

Additional file 1: Fig. S1. Nanoprobe purification step measured by ELISA. Fig. S2. DLS, zeta and fluorescence characterization of nanoprobes. Fig. S3. HER2 quantification on breast cancer xenograft by flow cytometry. Fig. S4. MRI biodistribution of nanoprobes in liver, spleen and kidneys